Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.
from The Medical News http://ift.tt/1BHsUIj
from The Medical News http://ift.tt/1BHsUIj
No comments:
Post a Comment